Lonial S, Lee HC, Badros A, et al. - An extended follow-up (13-month data cutoff) of patients with relapsed or refractory multiple myeloma (RRMM) who received belamaf 2.5 mg/kg in DREAMM-2 generated corroborative evidence that belamaf has a sustained clinical activity without new safety signals in a heavily pretreated patient population with RRMM.

• In DREAMM-2 (an ongoing, phase 2 study), belamaf (2.5 or 3.4 mg/kg) was tested in RRMM patients who experienced disease progression following ≥3 lines of therapy.

• Patients were refractory to immunomodulatory drugs and proteasome inhibitors and refractory and/or intolerant to an anti-CD38 therapy.

• Of 97 patients, 31 showed an overall response, and a very good partial response or better was obtained in 18 responders.

• Median duration of response, overall survival, and progression-free survival were 11.0 months, 13.7 months, and 2.8 months, respectively.